Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 9, 2009 - Issue 1
Submit an article Journal homepage
245
Views
20
CrossRef citations to date
0
Altmetric
Reviews

CD4+ T cells in antitumor immunity: utility of an Ii-Key HER2/neu hybrid peptide vaccine (AE37)

Elizabeth A Mittendorf Assistant Professor University of Texas MD Anderson Cancer Center, Department of Surgical Oncology, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA +1 713 792 2362; +1 713 792 0722; [email protected]
, MD,
Jarrod P Holmes Staff Physician Naval Medical Center, Division of Hematology and Medical Oncology, Department of Medicine, San Diego, 34800 Bob Wilson Drive, Suite 202, San Diego, CA 92134, USA
, MD,
James L Murray Professor University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA
, MD,
Eric von Hofe President Antigen Express, One Innovation Drive, Worcester, MA 01605, USA
, PhD &
George E Peoples Chief Brooke Army Medical Center, Department of Surgery, Surgical Oncology, General Surgery Service, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234, USA
, MD
Pages 71-78 | Published online: 08 Dec 2008

Bibliography

  • Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997;18(6):267-8
  • Mittendorf EA, Holmes JP, Ponniah S, et al. The E75 HER2/neu. peptide vaccine. Cancer Immunol Immunother 2008;57(10):1511-21
  • Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997;18(4):175-82
  • Van den Eynde B, Brichard VG. New tumor antigens recognized by T cells. Curr Opin Immunol 1995;7(5):674-81
  • Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96(9):3102-8
  • Disis ML, Grabstein KH, Sleath PR, et al. Generation of immunity to the HER-2/neu. oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999;5(6):1289-97
  • Fisk B, Blevins TL, Wharton JT, et al. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181(6):2109-17
  • Knutson KL, Schiffman K, Cheever MA, et al. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 2002;8(5):1014-18
  • Kono K, Takahashi A, Sugai H, et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 2002;8(11):3394-400
  • Murray JL, Gillogly ME, Przepiorka D, et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 2002;8(11):3407-18
  • Peoples GE, Holmes JP, Hueman MT, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: US. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008;14(3):797-803
  • Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer res 1998;58(21):4902-8
  • Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20(11):2624-32
  • Holmes JP, Benavides LC, Gates JD, et al. Results of the first Phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008;26(20):3426-33
  • Holmes JP, Gates JD, Benavides LC, et al. Optimal dose and schedule of a HER2/neu (E75) peptide vaccine to prevent breast cancer recurrence: United States Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2008;113(7):1666-75
  • Knutson KL, Disis ML. Augmenting T helper cell immunity in cancer. Curr Drug Targets 2005;5(4):365-71
  • Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005;54(8):721-8
  • Xu M, Li J, Gulfo JV, et al. MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases. Scand J Immunol 2001;54(1-2):39-44
  • Sotiriadou R, Perez SA, Gritzapis AD, et al. Peptide HER2(776 – 788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br J Cancer 2001;85(10):1527-34
  • Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998;188(12):2199-204
  • Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998;10(5):588-94
  • Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Nat Acad Sci USA 1993;90(8):3539-43
  • Levitsky HI, Lazenby A, Hayashi RJ, et al. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 1994;179(4):1215-24
  • Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4+ T cells in the antitumor immune response. J Exp Med 1998;188(12):2357-68
  • Gattinoni L, Powell DJ Jr, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev 2006;6(5):383-93
  • Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (New York) 2002;298(5594):850-4
  • Dissanayake SK, Thompson JA, Bosch JJ, et al. Activation of tumor-specific CD4+ T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res 2004;64(5):1867-74
  • Hillman GG, Kallinteris NL, Lu X, et al. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation. Cancer Treat Rev 2004;30(3):281-90
  • Altomonte M, Fonsatti E, Visintin A, et al. Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach? Oncogene 2003;22(42):6564-9
  • Bertolino P, Trescol-Biemont MC, Thomas J, et al. Death by neglect as a deletional mechanism of peripheral tolerance. Int Immunol 1999;11(8):1225-38
  • Maldonado-Lopez R, Moser M. Dendritic cell subsets and the regulation of Th1/Th2 responses. Semin Immunol 2001;13(5):275-82
  • Cheever MA, Chen W. Therapy with cultured T cells: principles revisited. Immunol Rev 1997;157:177-94
  • Fruh K, Yang Y. Antigen presentation by MHC class I and its regulation by interferon γ Curr opin immunol 1999;11(1):76-81
  • Tuttle TM, Anderson BW, Thompson WE, et al. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients. Clin Cancer Res 1998;4(8):2015-24
  • Disis ML, Cheever MA. HER-2/neu oncogenic protein: issues in vaccine development. Crit Rev Immunol 1998;18(1-2):37-45
  • Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001;107(4):477-84
  • Salazar LG, Fikes J, Southwood S, et al. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 2003;9(15):5559-65
  • Adams S, Albericio F, Alsina J, et al. Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC class II molecules. Arzneimittel-Forschung 1997;47(9):1069-77
  • Adams S, Humphreys RE. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules. Eur J Immunol 1995;25(6):1693-702
  • Kallinteris NL, Lu X, Blackwell CE, et al. Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines. Exp Opin Biol Ther 2006;6(12):1311-21
  • Bertolino P, Rabourdin-Combe C. The MHC class II-associated invariant chain: a molecule with multiple roles in MHC class II biosynthesis and antigen presentation to CD4+ T cells. Crit Rev Immunol 1996;16(4):359-79
  • Xu M, Jackson R, Adams S, et al. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1. Arzneimittel-Forschung 1999;49(9):791-9
  • Gillogly ME, Kallinteris NL, Xu M, et al. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother 2004;53(6):490-6
  • Humphreys RE, Adams S, Koldzic G, et al. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine 2000;18(24):2693-7
  • Voutsas IF, Gritzapis AD, Mahaira LG, et al. Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain. Int J Cancer 2007;121(9):2031-41
  • Benavides LC, Gates JC, Carmichael MG, et al. Response to a preventive HER2/neu peptide (E75) vaccine based on HER2/neu status. Proc American Association Cancer Res 2008;49:670
  • Jager E, Ringhoffer M, Dienes HP, et al. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 1996;67(1):54-62
  • Mittendorf EA, Storrer CE, Foley RJ, et al. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 2006;106(11):2309-17
  • Mittendorf EA, Peoples GE, Singletary SE. Breast cancer vaccines: promise for the future or pipe dream? Cancer 2007;110(8):1677-86

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.